Skip to content
drillr.ai

ATRA

Atara Biotherapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$8.29-1.19%

Price as of Jul 20, 2026

ATRA news

Atara Biotherapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 18, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities prior to May 20, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA. (https://bgandg.com/AT

    ACCESSWIRE ·

  2. Atara Biotherapeutics Announces Changes to Its Board of Directors

    Atara Biotherapeutics Announces Changes to Its Board of Directors Atara Biotherapeutics, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.atarabio.com%2F&esheet=54553065&newsitemid=20260612613594&lan=en-US&anchor=Atara+Biotherapeutics%2C+Inc.&index=1&md5=ac47280ffb8e94d8eed277fda2ce252d) (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer

    Business Wire ·

  3. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 4, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities prior to May 20, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA. (https://bgandg.com/ATR

    ACCESSWIRE ·

  4. Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 2, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities prior to May 20, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA. (https://bgandg.com/ATR

    ACCESSWIRE ·

  5. Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 31, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities prior to May 20, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA. (https://bgandg.com/ATR

    ACCESSWIRE ·

  6. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

    The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA PR Newswire NEW YORK, May 26, 2026 NEW YORK, May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). (https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.html) Shareholders who purchased shares of ATRA during the class period listed are encouraged to contact the firm

    PR Newswire ·

  7. Pomerantz LLP Announces Securities Class Action Against Pomerantz LLP – ATRA

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 23, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA) and certain officers.   The class action, filed in the United States District Court for the Central District of California, and docketed under 26-cv-03083, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise

    ACCESSWIRE ·

  8. Pomerantz LLP Reports Filing of Class Action Litigation Against Atara Biotherapeutics, Inc. – ATRA

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 22, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA) and certain officers.   The class action, filed in the United States District Court for the Central District of California, and docketed under 26-cv-03083, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise

    ACCESSWIRE ·

  9. ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

    ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that “develops therapies for patients with solid tumors, hema

    Business Wire ·

  10. Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

    New York, New York--(Newsfile Corp. - May 22, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Atara securities between May 20, 2024 an

    Newsfile Corp ·

  11. Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

    Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire LOS ANGELES, May 22, 2026 LOS ANGELES, May 22, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4694820-1&h=3195994076&u=https%3A%2F%2Fwww.glancylaw.com%2F&a=Glancy+Prongay+Wolke+%26+Rotter+LLP) announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Atara Bioth

    PR Newswire ·

  12. ATRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 22 Deadline in Securities Class Action - ATRA

    NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”), of the important May 22, 2026 lead plaintiff deadline. SO WHAT: If you purchased Atara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement

    Globe Newswire ·

  13. ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

    ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.faruqilaw.com%2Fattorney%2F22%2Fjames-m-wilson-jr&esheet=54539506&newsitemid=20260522281496&lan=en-US&anchor=James+%28Josh%29+Wilson&index=1&md5=1b00ec355962d2bdf275876b1a5d2d06) Encourages Investors Who Suffer

    Business Wire ·

  14. ATARA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

    New York, New York--(Newsfile Corp. - May 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026, inclusive (the "Class Period"), of the important May 22, 2026 lead plaintiff deadline. SO WHAT: If you purchased Atara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a

    Newsfile Corp ·

  15. ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit

    Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker (https://www.globenewswire.com/Tracker?data=NKnJpT98C9m69Sv58MHAI4y7b4GkauFL-7bKMNGdJpKRs1zubNypIqOpQmZXlIlvoVVRy2ev8E2EIJ4EI1Eo5xbEY2OyLsN5MSg8k3eRxXb89zHVkVTF3Tzk1LSqsJ9q) Encourages Investors Who Suffered Losses In Atara (ATRA) To Contact Him Directly To Discuss Their Options If you purchased or acquired Atara securities between May 20, 2024 and January 9, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squir

    Globe Newswire ·

  16. DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

    BENSALEM, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to howardsmith@h

    Globe Newswire ·

  17. ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

    LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm (https://www.globenewswire.com/Tracker?data=mGMbJ2zde2T6l12qC_vVPtzrAg3WEK_LjV05Pf7mC2otfScNRzZM5tpcoVsajXRl3W3bS-jU0MQUTyJ1NAH8BHx68WzUZZO76r48Os6RY_U=), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA (https://www.globenewswire.com/Tracker?data=INh1X9bcGdFjkIOCpOH9tXManEHgAiQGI0GIlMr8h8Af1Niu6fGOAExxhQ-MCfve6Jy

    Globe Newswire ·

  18. ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

    ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 PR Newswire NEW YORK, May 21, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4692392-1&h=1193721984&u=https%3A%2F%2Fwww.faruqilaw.com%2Fattorney%2F22%2Fjames-m-wilson-jr&a=James+(Josh)+Wilson) Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To D

    PR Newswire ·

  19. ATARA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 20, 2026 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) between May 20, 2024 and January 9, 2026, inclusive (the "Class Period"), of the important May 22, 2026 lead plaintiff deadline. SO WHAT: If you purchased Atara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c

    ACCESSWIRE ·

  20. Pomerantz LLP Reports Filing of Class Action Lawsuit Against Atara Biotherapeutics, Inc. – ATRA

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 20, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA) and certain officers.   The class action, filed in the United States District Court for the Central District of California, and docketed under 26-cv-03083, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise

    ACCESSWIRE ·